RGNX REGENXBIO Inc

Price (delayed)

$26.5

Market cap

$1.14B

P/E Ratio

10.95

Dividend/share

N/A

EPS

$2.42

Enterprise value

$1.04B

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, ...

Highlights
The net income has soared by 183% YoY but it is down by 21% from the previous quarter
RGNX's EPS has surged by 178% year-on-year but it is down by 20% since the previous quarter
The quick ratio has declined by 39% year-on-year and by 6% since the previous quarter
REGENXBIO's debt has increased by 14% YoY

Key stats

What are the main financial stats of RGNX
Market
Shares outstanding
43.13M
Market cap
$1.14B
Enterprise value
$1.04B
Valuations
Price to earnings (P/E)
10.95
Price to book (P/B)
1.65
Price to sales (P/S)
2.4
EV/EBIT
7.39
EV/EBITDA
6.89
EV/Sales
2.19
Earnings
Revenue
$473.68M
EBIT
$140.32M
EBITDA
$150.55M
Free cash flow
$139.97M
Per share
EPS
$2.42
Free cash flow per share
$3.26
Book value per share
$16.06
Revenue per share
$11.03
TBVPS
$23.88
Balance sheet
Total assets
$1.03B
Total liabilities
$335.7M
Debt
$87.69M
Equity
$689.67M
Working capital
$326.94M
Liquidity
Debt to equity
0.13
Current ratio
3.73
Quick ratio
3.55
Net debt/EBITDA
-0.71
Margins
EBITDA margin
31.8%
Gross margin
86.8%
Net margin
21.4%
Operating margin
28%
Efficiency
Return on assets
10.7%
Return on equity
16.7%
Return on invested capital
21.2%
Return on capital employed
15.5%
Return on sales
29.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RGNX stock price

How has the REGENXBIO stock price performed over time
Intraday
0.11%
1 week
25.65%
1 month
36.95%
1 year
-34.16%
YTD
-18.96%
QTD
-20.16%

Financial performance

How have REGENXBIO's revenue and profit performed over time
Revenue
$473.68M
Gross profit
$410.98M
Operating income
$132.5M
Net income
$101.26M
Gross margin
86.8%
Net margin
21.4%
The net income has soared by 183% YoY but it is down by 21% from the previous quarter
RGNX's operating margin has soared by 135% year-on-year but it is down by 18% since the previous quarter
REGENXBIO's net margin has surged by 127% YoY but it has decreased by 21% QoQ
The company's operating income fell by 17% QoQ

Growth

What is REGENXBIO's growth rate over time

Valuation

What is REGENXBIO stock price valuation
P/E
10.95
P/B
1.65
P/S
2.4
EV/EBIT
7.39
EV/EBITDA
6.89
EV/Sales
2.19
RGNX's EPS has surged by 178% year-on-year but it is down by 20% since the previous quarter
RGNX's P/B is 55% below its 5-year quarterly average of 3.7 and 41% below its last 4 quarters average of 2.8
The equity has grown by 24% YoY but it has contracted by 10% from the previous quarter
The price to sales (P/S) is 91% lower than the 5-year quarterly average of 26.8 and 73% lower than the last 4 quarters average of 8.8

Efficiency

How efficient is REGENXBIO business performance
The ROIC has soared by 183% YoY but it has contracted by 23% from the previous quarter
The ROE has soared by 160% YoY but it is down by 25% QoQ
REGENXBIO's ROA has soared by 157% YoY but it has decreased by 24% from the previous quarter
RGNX's return on sales has surged by 142% year-on-year but it is down by 17% since the previous quarter

Dividends

What is RGNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RGNX.

Financial health

How did REGENXBIO financials performed over time
The quick ratio has declined by 39% year-on-year and by 6% since the previous quarter
The current ratio has contracted by 37% YoY and by 6% from the previous quarter
REGENXBIO's debt is 87% lower than its equity
The equity has grown by 24% YoY but it has contracted by 10% from the previous quarter
RGNX's debt to equity is up by 18% since the previous quarter but it is down by 7% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.